Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glyceraldehyde-3-phosphate dehydrogenase pseudogene 34 (GAPDHP34) is a processed pseudogene—a segment of DNA that resembles the mRNA-derived sequence of the functional GAPDH gene but lacks protein-coding capability[2][3][5]. While the parental gene GAPDH is an essential enzyme in glycolysis with multiple cellular functions and roles in diseases, pseudogenes like GAPDHP34 have no known protein product, physiological function, or direct disease association. GAPDHP34 is one of many GAPDH pseudogenes found in the human genome, reflecting evolutionary processes and the high retrotranspositional activity of the GAPDH gene[3][5]. It is not a therapeutic drug target, receptor, or enzyme and holds no role in drug interaction or biomarker utility[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glyceraldehyde-3-phosphate dehydrogenase pseudogene 34 (GAPDHP34).